RESUMEN
Introduction: In 2016, the ?rst results of phase III clinical trials showed bene?cial effects of CBD in treatment-resistant seizure disorders, To evaluate the ef?cacy of cannabidiol in patients with Objective: drug resistant epilepsy in a private third-level hospital. Descriptive, retrospective, observational and cross-sectional Methods: study. Inclusion criteria were patients under treatment with cannabidiol and drug resistant epilepsy from January 2017 to March 2022. Study variables were age, gender, evolution of epilepsy (years), epileptic syndromes, numbers of antiseizure drugs, reduction of seizures (more tan 50%), cannabidiol dose (mg/kg/day), treatment time (months) and adverse effects. Information was captured in Excel and analyzed in SPSS. 31 patients. The epileptic syndromes found were Lennox Gastaut 32%, Results: West 12.9%, Dravet 3.2%, Doose 3.2% and no syndromic 48.3%. Reduction of seizures more than 50% was shown in 25 patients (80.6%). Seizure free in 5 patients (16%). Cannabidiol dose was: <1 mg/kg/day (9.6%), 1-5 mg/kg/day (77.4%), >5 mg/kg/day (12.9%). Association was found between a decrease in the number of seizures and a higher dose of cannabidiol with statistical signi?cance (p<0.05). Our study suggests that cannabidiol reduces seizures with few adverse effects in drug Conclusion: resistant epilepsy